Αντιπροσωπευτικές δημοσιεύσεις την τελευταία πενταετία

1. Kei A, Liberopoulos E, Tellis K, Rizzo M, Elisaf M, Tselepis A. Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial. Eur J Clin Invest. 2013; 43: 698-707.
2. Filippatos TD, Rizos EC, Tsimihodimos V, Gazi IF, Tselepis AD, Elisaf MS. Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A₂ in subjects with prediabetes. Lipids. 2013; 48: 547-55.
3. Rizos CV, Liberopoulos EN, Tellis CC, Tselepis AD, Elisaf MS. The effect of combining rosuvastatin with sartans of different peroxisome proliferator receptor-γ activating capacity on plasma 8-isoprostane prostaglandin F2a levels. Arch Med Sci. 2013; 9: 172-6.
4. Pappas-Gogos G, Tellis C, Lasithiotakis K, Tselepis AD, Tsimogiannis K, Tsimoyiannis E, Chalkiadakis G, Chrysos E. Oxidative stress markers in laparoscopic versus open colectomy for cancer: a double-blind randomized study. Surg Endosc. 2013; 27: 2357-65.
5. Tellis CC, Moutzouri E, Elisaf M, Wolfert RL, Tselepis AD. The elevation of apoB in hypercholesterolemic patients is primarily attributed to the relative increase of apoB/Lp-PLA2. J Lipid Res. 2013; 54: 3394-402.
6. Moutzouri E, Liberopoulos EN, Tellis CC, Milionis HJ, Tselepis AD, Elisaf MS. Comparison of the effect of simvastatin versus simvastatin/ezetimibe versus rosuvastatin on markers of inflammation and oxidative stress in subjects with hypercholesterolemia. Atherosclerosis. 2013; 231: 8-14.
7. Liberopoulos EN, Apostolou F, Gazi IF, Kostara C, Bairaktari ET, Tselepis AD, Elisaf M. Visceral leishmaniasis is associated with marked changes in serum lipid profile. Eur J Clin Invest. 2014; 44: 719-27.
8. Kei A, Tellis C, Liberopoulos E, Tselepis A, Elisaf M. Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia. Cardiovasc Ther. 2014; 32: 139-46.
9. Stamatelopoulos K, Sibbing D, Rallidis LS, Georgiopoulos G, Stakos D, Braun S, Gatsiou A, Sopova K, Kotakos C, Varounis C, Tellis CC, Kastritis E, Alevizaki M, Tselepis AD, Alexopoulos P, Laske C, Keller T, Kastrati A, Dimmeler S, Zeiher AM, Stellos K. Amyloid-beta (1-40) and the risk of death from cardiovascular causes in patients with coronary heart disease. J Am Coll Cardiol. 2015; 65: 904-16.
10. Rizos CV, Kostapanos MS, Rizos EC, Tselepis AD, Elisaf MS. The effect of Rosuvastatin in Low-Density Lipoprotein subfractions in patients with impaired fasting glucose: A Clinical study. J. Cardiovascular Pharmacology Therapeutics. 2015; 20(3): 276-283.
11. Ntalas IV, Kalantzi KI, Tsoumani ME, Bourdakis A, Charmpas C, Christogiannis Z, Dimoulis N, Draganigos A, Efthimiadis I, Giannakoulas G, Giatrakos I, Giogiakas V, Goumas G, Hatziathanasiou G, Kazakos E, Kipouridis N, Konstantinou S, Milionis H, Nikolopoulos D, Peltekis L, Prokopakis N, Sinteles I, Stroumbis C, Terzoudi K, Thoma M, Tsilias K, Vakalis I, Vardakis K, Vasilakopoulos V, Vemmos K, Voukelatou M, Xaraktsis I, Panagiotakos DB, Goudevenos JA, Tselepis AD. Salts of Clopidogrel: Investigation to Ensure Clinical Equivalence: A 12-Month Randomized Clinical Trial. J Cardiovasc Pharmacol Ther. 2016; 21: 516-525.
12. Chantzichristos VG, Agouridis AP, Moutzouri E, Stellos K, Elisaf MS, Tselepis AD. Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study. Curr Vasc Pharmacol. 2016; 14: 474-480.
13. Chantzichristos VG, Agouridis AP, Moutzouri E, Stellos K, Elisaf MS, Tselepis AD. Effect of rosuvastatin or its combination with omega-3 fatty acids on circulating CD34(+) progenitor cells and on endothelial colony formation in patients with mixed dyslipidaemia. Atherosclerosis. 2016; 251: 240-247.
14. Kontogianni VG, Tsoumani ME, Kellici TF, Mavromoustakos T, Gerothanassis IP, Tselepis AD, Tzakos AG. Deconvoluting the Dual Antiplatelet Activity of a Plant Extract. J Agric Food Chem. 2016; 64: 4511-21.
15. Stylos E, Chatziathanasiadou MV, Tsiailanis A, Kellici TF, Tsoumani M, Kostagianni AD, Deligianni M, Tselepis AD, Tzakos AG. Tailoring naringenin conjugates with amplified and triple antiplatelet activity profile: Rational design, synthesis, human plasma stability and in vitro evaluation. Biochim Biophys Acta. 2017; 1861: 2609-2618.
16. Zvintzou E, Lhomme M, Chasapi S, Filou S, Theodoropoulos V, Xapapadaki E, Kontush A, Spyroulias G, Tellis CC, Tselepis AD, Constantinou C, Kypreos KE. Pleiotropic effects of apolipoprotein C3 on HDL functionality and adipose tissue metabolic activity. J Lipid Res. 2017; 58: 1869-1883.
17. Moschonas IC, Kellici TF, Mavromoustakos T, Stathopoulos P, Tsikaris V, Magafa V, Tzakos AG, Tselepis AD. Molecular requirements involving the human platelet protease-activated receptor-4 mechanism of activation by peptide analogues of its tethered-ligand. Platelets. 2017; 28: 812-821.
18. Tatsidou PT, Chantzichristos VG, Tsoumani ME, Sidiropoulou S, Ntalas IV, Goudevenos JA, Stellos K, Tselepis AD. Circulating progenitor cells and their interaction with platelets in patients with an acute coronary syndrome. Platelets. 2018; 16: 1-8.
19. Chantzichristos VG, Gkrozou F, Stellos K, Paschopoulos ME, Tselepis AD. Comparative Anti-Platelet Profiling Reveals a Potent Anti-Aggregatory Effect of CD34+ Progenitor Cell-Derived Late-Outgrowth Endothelial Cells in vitro. J Vasc Res. 2018; 55(1): 13-25.